Adaptive Biotechnologies Corp (ADPT)
8.405
+0.56
(+7.21%)
USD |
NASDAQ |
Mar 24, 16:00
8.405
0.00 (0.00%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.204B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -40.70% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 6.464 |
| Price to Book Value | 2.594 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
News
Headline
Wire
Time (ET)
Yahoo
03/09 09:55
Yahoo
02/27 16:05
Yahoo
02/21 09:55
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 05/04/2023* | 16:30 EST | Earnings Call | Q1 2023 | -- | -- | -- | |
| 05/04/2023* | -- | Results | Q1 2023 | -- | -0.36 | -- | |
| 02/14/2023 | 16:30 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 02/14/2023 | -- | Results | Q4 2022 | -0.28 | -0.35 | 19.71% | |
| 11/03/2022 | 16:30 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 11/03/2022 | -- | Results | Q3 2022 | -0.32 | -0.38 | 14.74% | |
| 08/03/2022 | 16:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 08/03/2022 | -- | Results | Q2 2022 | -0.37 | -0.43 | 13.65% |
*Estimated Date/Time
Earnings
Profile
Edit
| Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (“MRD”) in patients with multiple myeloma (“MM”), B cell acute lymphoblastic leukemia (“ALL”) and chronic lymphocytic leukemia (“CLL”) and is also available as a CLIA-validated laboratory developed test (“LDT”) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (“DLBCL”). |
| URL | https://www.adaptivebiotech.com |
| Investor Relations URL | https://investors.adaptivebiotech.com/ |
| HQ State/Province | Washington |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | May. 04, 2023 (est.) |
| Last Earnings Release | Feb. 14, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 23, 2023.
Fundamentals
| Revenue (TTM) | 185.31M |
| Total Expenses (TTM) | 385.49M |
| Net Income (TTM) | -200.25M |
| Total Assets (Quarterly) | 856.62M |
| Total Liabilities (Quarterly) | 392.52M |
| Shareholders Equity (Quarterly) | 464.16M |
| Cash from Operations (TTM) | -183.94M |
| Cash from Investing (TTM) | 2.905M |
| Cash from Financing (TTM) | 132.26M |
Ratings
Profile
Edit
| Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (“MRD”) in patients with multiple myeloma (“MM”), B cell acute lymphoblastic leukemia (“ALL”) and chronic lymphocytic leukemia (“CLL”) and is also available as a CLIA-validated laboratory developed test (“LDT”) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (“DLBCL”). |
| URL | https://www.adaptivebiotech.com |
| Investor Relations URL | https://investors.adaptivebiotech.com/ |
| HQ State/Province | Washington |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | May. 04, 2023 (est.) |
| Last Earnings Release | Feb. 14, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| ADPT Tweets |